Abstract
A 34-yr-old nulliparous black woman presented with hair loss, facial hirsutism, irregular menses and infertility associated with greatly increased serum total testosterone levels. The adrenal glands and the ovaries were normal on radiological and ultrasonographic investigation. Catheterization of the veins draining from the adrenal glands and the ovaries yielded testosterone levels of 20.3 nmol/L and 20.0 nmo/L in the right and the left adrenal veins, respectively, and 17.9 nmol/L and 27.4 nmol/L in the right and left ovaries venous plexus, respectively. Sequencial dexamethasone and ethynyl estradiol suppression test showed a decrease in cortisol level with no change in total testosterone level on dexamethasone while an increase in testosterone from 10.5 nmol/L to 20.1 nmol/L was observed ten days after ethynil estradiol had been associated to dexamethasone. When a gonadotropin-releasing hormone agonist (gonadorelin 3.5 mg IM) was administered for 2 months, serum gonadotropins levels decreased to less than 2 IU/L, total testosterone to 3.8 nmol/L and estradiol to less than 36 pmol/L. The patient was submitted to a pelvic exploratory laparotomy and a left salpingo-oophorectomy was performed. A solid and circumscribed ovarian tumor of 1.0 cm in diameter was found. The pathological diagnosis was a Leydig cell tumor with surrounding stromal hyperplasia. These findings may suggest that this tumor was gonadotropin-dependent being indirectly stimulated by ethynil estradiol, through a sensitization of the pituitary gonadotropes and increase in gonadotropin levels and suppressed by a gonadotropin-releasing hormone agonist.
Similar content being viewed by others
References
Scully R.E. Ovarian tumors with endocrine manifestation. In: DeGroot L., (Ed), Endocrinology. W. B. Saunders Company, Philadelphia, 1989, p. 1473
Marcondes J.A.M. Sindromes adrenogenitalis. In: Wajchenberg B.L. (Ed.), Tratado de endocrinologia clinica. Rocca, São Paulo, 1992, p. 483.
Kennedy L., Traub A.T., Atkinson A.B., Sheridan B. Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor. J. Clin. Endocrinol. Metab. 64: 1320, 1987.
Parr J.H., Abraham R.R., Seed M., Short F., Wynn V. The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist. J. Endocrinol. Invest. 11: 433, 1988.
Steingold KA, Judd H.L., Nieberg R.K., Lu J.K.H., Chang R.J. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am. J. Obstet. Gynecol. 154: 1241, 1986.
Abraham G.E. Radioimmunoassay of steroids in biological material. Acta Endocrinol. (Copenh) (Suppl.) 1: 183, 1975.
Dunaif A., Scully R.E., Andersen R.N., Chapin D. S., Crowley Jr W.F. The effects of continuous androgen secretion on the hypothalamic-pituitary axis in women: evidence from a luteinized thecoma of the ovary. J. Clin. Endocrinol. Metab. 59: 389, 1984.
Yen S.C.C. The polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 12: 177, 1980.
Abrahamsson G., Dahlgren E., Hahtlin M., Knutson F., Norstrom A., Janson P.O. In vitro production of cyclic AMP and steroids from an ovarian Sertoli-Leydig cell tumor. Acta Obstet. Gynecol. Scand. 74: 310, 1995.
Lamberts S.W.J., Timmers J.M., Oosterom R. Testosterone secretion by culture arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist. J. Clin. Endocrinol. Metab. 54: 450, 1982.
Ory S.L Clinical uses of luteinizing hormone-releasing hormone. Fertil. Steril. 39: 577, 1983.
Marcondes J.A.M., Abujamra A.C., Minanni S.L., Mendonpa B.B., Nery M., Lerario A.C., Pereira M.A.A., Abelin N., Wajchenberg B.L. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Horm. Metab. Res. 25: 105, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marcondes, J.A.M., Nery, M., Mendonça, B.B. et al. A virilizing Leydig cell tumor of the ovary associated with stromal hyperplasia under gonadotropin control. J Endocrinol Invest 20, 685–689 (1997). https://doi.org/10.1007/BF03348033
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348033